Treatment of Metastatic Tumors of the Urogenital Area (Bladder Cancer, Renal Cancel) With Cytokine-induced Killer Cells
试验速览
- 阶段
- 1 期
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- The relapse-free survival
研究概览
简要总结
Treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells
详细描述
Treatment of metastatic tumors of the urogenital area using autologous cytokine-induced killer cells
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically confirmed diagnosis of pTa metastatic tumors of the urogenital area;
- •Patient who require repetitive transurethral resection;
- •Expression of muc-1/wt-1 by the tumor;
- •EGOC 0-3;
排除标准
- •any medical condition which can be associated with the high risk for the patient;
- •pregnancy/lactation;
- •chronic infections, including hepatitis B/C, tuberculosis, HIV
研究组 & 干预措施
Cytokine-induced killer cells
Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells
干预措施: Standard treatment according to the Clinical protocols (Other)
Control
Patients with metastatic tumors of the urogenital area receiving standard treatment
干预措施: Standard treatment according to the Clinical protocols (Other)
Cytokine-induced killer cells
Patients with the metastatic tumors of the urogenital area receiving standard treatment and autologous cytokine-induced killer cells
干预措施: cytokine-induced killer cells (Biological)
结局指标
主要结局
The relapse-free survival
时间窗: 3 year
The duration of relapse-free survival
Adverse effects associated with the therapy
时间窗: 1 year
Determination of adverse effects associated with the therapy
The relapse-free survival
时间窗: 1 year
The duration of relapse-free survival
The relapse-free survival
时间窗: 2 year
The duration of relapse-free survival
Adverse effects associated with the therapy
时间窗: 1 month
Determination of adverse effects associated with the therapy
次要结局
未报告次要终点